DrugMonitor™ Anti-Girentuximab Antibody (VS-1224-YC521)
CAT#: VS-1224-YC521
Girentuximab is a chimeric (mouse/human) monoclonal antibody targeting carbonic anhydrase IX, expressed in 95% of clear cell renal cell carcinomas (RCC). The DrugMonitor™ Anti-Girentuximab Antibody (VS-1224-YC521) is an anti-drug antibody (ADA) against Girentuximab. This drug-based antibody is raised in mice immunized with the Girentuximab. The anti-Girentuximab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Girentuximab in samples.
Specifications
- Host Animal
- Mouse
- Specificity
- Girentuximab
- Target
- Girentuximab
- Immunogen
- Girentuximab
- Type
- Mouse IgG
- Species Reactivity
- Human
- Purity
- >95%
- Purification
- Protein G
- Applications
- ELISA, PK/PD, ADA control
- Format
- Liquid
- Concentration
- Batch-dependent
- Buffer
- PBS, pH 7.4
- Preservative
- No preservatives
- Storage
- Store at 4°C for 1-2 weeks and at -20°C for 1 year. Avoid repeated freezing and thawing.
- Generic name
- Girentuximab
Customer Review
There are currently no Customer reviews or questions for VS-1224-YC521. Click the button above to contact us or submit your feedback about this product.
Submit Your Publication
Published with our product? Submit your paper and receive a 10% discount on your next order! Share your research to earn exclusive rewards.
Downloadable Resources
Download resources about recombinant antibody development and antibody engineering to boost your research.
Datasheet
MSDS
COA
Certificate of Analysis LookupTo download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
See other products for "Girentuximab"
Anti-CAIX/CA9 Recombinant Antibody (Girentuximab)Recombinant chimeric antibody expressed in CHO binding to human CAIX. Girentuximab is a chimeric monoclonal antibody designed for the treatment of renal cell carcinoma.
Afuco™ Anti-CA9 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-H43)This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Chimeric antibody to Human CA9.
Popular Products
Application: ELISA, Neut, IF, IP, FC, FuncS
Application: WB, ELISA, IP, FC, FuncS, Neut, IF
Application: FC, IHC, FuncS, Inhib, Cyt
Application: Inhib, Cyt
Application: ELISA
Application: WB, ELISA, IF, FuncS, Apop, BA
Application: WB, ELISA, FuncS, Inhib, PK, IP, SPR
Application: Neut, ELISA, IF, IP, FuncS, FC
Application: ELISA, Neut, FuncS
Application: ELISA, Neut
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.